Comparative Pharmacology
Head-to-head clinical analysis: CAPECITABINE versus SIKLOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPECITABINE versus SIKLOS.
CAPECITABINE vs SIKLOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Capecitabine is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and incorporates into RNA and DNA, leading to cytotoxic effects.
Hydroxyurea inhibits ribonucleotide reductase, reducing the synthesis of deoxyribonucleotides and thereby decreasing DNA synthesis. In sickle cell disease, it increases fetal hemoglobin (HbF) levels, which inhibits sickling of red blood cells.
Oral, 1250 mg/m2 twice daily for 2 weeks followed by a 1-week rest period.
100–200 mg/kg/day orally in two divided doses, not to exceed 200 mg/kg/day.
None Documented
None Documented
The terminal elimination half-life of capecitabine is approximately 0.75 hours. For its active metabolite 5-fluorouracil, the half-life is about 0.7 hours. Clinically, this short half-life necessitates twice-daily dosing to maintain therapeutic levels.
Clinical Note
moderateCapecitabine + Digoxin
"Capecitabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCapecitabine + Digitoxin
"Capecitabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCapecitabine + Deslanoside
"Capecitabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCapecitabine + Acetyldigitoxin
"Capecitabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 2-5 hours in adults; shorter in children (1-2 hours). Clinical context: requires thrice-daily dosing to maintain therapeutic concentrations; longer half-life in hepatic impairment (up to 10 hours).
Capecitabine is predominantly eliminated renally. Approximately 95.5% of the administered dose is recovered in urine, with 61% as unchanged capecitabine and its metabolites. Fecal excretion accounts for about 2.6%. Biliary elimination is minimal (<1%).
Primarily hepatic metabolism via CYP3A4; renal excretion of metabolites accounts for approximately 70-80% of the dose, with <1% excreted unchanged in urine. Fecal excretion is minor (<5%).
Category D/X
Category C
Antimetabolite
Antimetabolite